Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
14.25
Dollar change
-1.75
Percentage change
-10.94
%
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand22.24M Perf Week-
Market Cap316.92M Forward P/E- EPS next Y- Insider Trans- Shs Float10.52M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh-5.71 P/B- EPS next Y- ROA- Short Interest- Perf Year-
Cash/sh5.43 P/C2.62 EPS next 5Y- ROE- 52W Range- - - Perf YTD0.00%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High- Beta-
Dividend TTM- Quick Ratio13.27 Sales past 5Y- Gross Margin- 52W Low- ATR (14)1.14
Dividend Ex-Date- Current Ratio13.27 EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility- -
Employees72 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / No LT Debt/Eq- EPS Q/Q- Payout- Rel Volume- Prev Close16.00
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume- Price14.25
SMA20- SMA50- SMA200- Trades Volume1,754,117 Change-10.94%
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.